{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T22:45:36Z","timestamp":1695768336361},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Tuberculosis (TB) is the major cause of mortality in HIV-infected children globally. Current guidelines about the management of antiretroviral therapy in children with TB are based on a limited number of nonrandomized studies involving small numbers of participants. The aim of the study was to systematically retrieve and critically appraise available evidence on the efficacy and safety of different antiretroviral regimens in children with HIV infection who are receiving treatment for active TB.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a systematic review of the literature according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Records were retrieved through March 2016 from Medline, Embase and manual screening of key conference proceedings. Four specific research questions assessing available treatment options were defined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Although 4 independent searches were conducted (1 for each Population, Intervention, Comparator, Outcomes question), results were elaborated and interpreted together because of significant overlap among the retrieved records. Six observational studies were selected for qualitative synthesis while meta-analysis could not be performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Evidence for optimal treatment options for HIV\/TB coinfected children is limited. As the global community strives to reach the fast-track HIV treatment targets and eliminate childhood TB deaths, it must ensure that coinfected children are included in key treatment studies and expand this neglected but crucial area of research.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001784","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T19:59:19Z","timestamp":1504900759000},"page":"e117-e125","source":"Crossref","is-referenced-by-count":6,"title":["Antiretroviral Therapy in HIV-Infected Children With Tuberculosis"],"prefix":"10.1097","volume":"37","author":[{"given":"Giorgia","family":"Sulis","sequence":"first","affiliation":[{"name":"University Department of Infectious and Tropical Diseases, WHO Collaborating Centre for TB\/HIV co-infection and for TB elimination, University of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Amadasi","sequence":"additional","affiliation":[{"name":"University Department of Infectious and Tropical Diseases, WHO Collaborating Centre for TB\/HIV co-infection and for TB elimination, University of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Odone","sequence":"additional","affiliation":[{"name":"Unit of Public Health, Department of Biomedical, Biotechnological and Translational Sciences, University of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Penazzato","sequence":"additional","affiliation":[{"name":"HIV\/AIDS Department, World Health Organization, Geneva, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Matteelli","sequence":"additional","affiliation":[{"name":"University Department of Infectious and Tropical Diseases, WHO Collaborating Centre for TB\/HIV co-infection and for TB elimination, University of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jpids\/piu020","article-title":"Tuberculosis in pediatric antiretroviral therapy programs in low- and middle-income countries: diagnosis and screening practices.","volume":"4","author":"Ballif","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.5588\/ijtld.12.0740","article-title":"Impact of expanded antiretroviral use on incidence and prevalence of tuberculosis in children with HIV in Kenya.","volume":"17","author":"Abuogi","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/INF.0000000000001062","article-title":"Tuberculosis infection in early childhood and the association with HIV-exposure in HIV-uninfected children in rural Uganda.","volume":"35","author":"Marquez","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1097\/QAD.0000000000000259","article-title":"Improving antiretroviral therapy scale-up and effectiveness through service integration and decentralization.","volume":"28(suppl 2)","author":"Suthar","year":"2014","journal-title":"AIDS"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12916-016-0593-7","article-title":"Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.","volume":"14","author":"Crook","year":"2016","journal-title":"BMC Med"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3018(15)00137-X","article-title":"Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis.","volume":"2","author":"Ford","year":"2015","journal-title":"Lancet HIV"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"e1001907","DOI":"10.1371\/journal.pmed.1001907","article-title":"The HIV treatment gap: estimates of the financial resources needed versus available for scale-up of antiretroviral therapy in 97 countries from 2015 to 2020.","volume":"12","author":"Dutta","year":"2015","journal-title":"PLoS Med"},{"key":"R12-20230912","first-page":"392","article-title":"The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era.","volume":"8","author":"Marais","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5588\/ijtld.15.0471","article-title":"Counting children with tuberculosis: why numbers matter.","volume":"19","author":"Seddon","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0140-6736(14)60195-1","article-title":"Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates.","volume":"383","author":"Jenkins","year":"2014","journal-title":"Lancet"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1086\/651454","article-title":"Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.","volume":"201","author":"Reitz","year":"2010","journal-title":"J Infect Dis"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"e17273","DOI":"10.1371\/journal.pone.0017273","article-title":"Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.","volume":"6","author":"Frohoff","year":"2011","journal-title":"PLoS One"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAD.0b013e32833f9e04","article-title":"Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART.","volume":"25","author":"Zanoni","year":"2011","journal-title":"AIDS"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"e55111","DOI":"10.1371\/journal.pone.0055111","article-title":"Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.","volume":"8","author":"van Dijk","year":"2013","journal-title":"PLoS One"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/QAI.0000000000000284","article-title":"The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.","volume":"67","author":"Soeters","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1001\/jama.2013.3710","article-title":"Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.","volume":"309","author":"Lowenthal","year":"2013","journal-title":"JAMA"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/QAI.0b013e31805c9d52","article-title":"High prevalence of subtherapeutic plasma concentrations of efavirenz in children.","volume":"45","author":"Ren","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QAI.0b013e3181642257","article-title":"Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.","volume":"47","author":"Ren","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00228-010-0847-9","article-title":"Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.","volume":"66","author":"Elsherbiny","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3851\/IMP1757","article-title":"Lopinavir exposure is insufficient in children given double doses of lopinavir\/ritonavir during rifampicin-based treatment for tuberculosis.","volume":"16","author":"McIlleron","year":"2011","journal-title":"Antivir Ther"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3851\/IMP1915","article-title":"Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.","volume":"17","author":"Zhang","year":"2012","journal-title":"Antivir Ther"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bcp.12101","article-title":"Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.","volume":"76","author":"Zhang","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dku382","article-title":"Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir\/ritonavir.","volume":"70","author":"Moultrie","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02752276","article-title":"Clinical manifestations and management of pediatric HIV infection.","volume":"68","author":"Kaul","year":"2001","journal-title":"Indian J Pediatr"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jpids\/piu032","article-title":"Predictors of treatment failure in HIV-positive children receiving combination antiretroviral therapy: cohort data from Mozambique and Uganda.","volume":"4","author":"Costenaro","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/INF.0000000000000452","article-title":"Diagnosis and treatment of tuberculosis among children at an HIV care program in Dar es Salaam, Tanzania.","volume":"33","author":"Adams","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1097\/QAD.0b013e328360dbb4","article-title":"Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.","volume":"27","author":"McIlleron","year":"2013","journal-title":"AIDS"},{"key":"R37-20230912","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0b013e31819c33a3","article-title":"Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.","volume":"50","author":"Ren","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/11593330-000000000-00000","article-title":"Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents.","volume":"13","author":"Eley","year":"2011","journal-title":"Paediatr Drugs"},{"key":"R39-20230912","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/17425250903393752","article-title":"Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.","volume":"6","author":"Kwara","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R40-20230912","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/1756-0500-4-511","article-title":"AtriplaR\/anti-TB combination in TB\/HIV patients. Drug in focus.","volume":"4","author":"Semvua","year":"2011","journal-title":"BMC Res Notes"},{"key":"R41-20230912","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0b013e32830437df","article-title":"Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.","volume":"22","author":"Prendergast","year":"2008","journal-title":"AIDS"},{"key":"R42-20230912","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/QAD.0b013e3283550e20","article-title":"Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.","volume":"26","author":"Oudijk","year":"2012","journal-title":"AIDS"},{"key":"R43-20230912","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bcp.12934","article-title":"The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.","volume":"82","author":"Bienczak","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"R44-20230912","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","article-title":"Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.","volume":"53","author":"Regazzi","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R45-20230912","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","article-title":"A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.","volume":"48","author":"Manosuthi","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R46-20230912","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0140-6736(12)62198-9","article-title":"Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): A 5-year open-label randomised factorial trial.","volume":"381","author":"Gibb","year":"2013","journal-title":"Lancet"},{"key":"R47-20230912","first-page":"1109","article-title":"Design of regimens for treating tuberculosis in patients with HIV infection, with particular reference to sub-Saharan Africa.","volume":"5","author":"Harries","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"R48-20230912","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(00)04639-0","article-title":"Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1.","volume":"357","author":"Harries","year":"2001","journal-title":"Lancet"},{"key":"R49-20230912","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00002030-199903110-00001","article-title":"The treatment of tuberculosis in HIV-infected persons.","volume":"13","author":"Pozniak","year":"1999","journal-title":"AIDS"},{"key":"R50-20230912","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/14656566.2017.1309023","article-title":"Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.","volume":"18","author":"Rabie","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"R51-20230912","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/QAD.0b013e32835a67fb","article-title":"No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients.","volume":"27","author":"Singh","year":"2013","journal-title":"AIDS"},{"key":"R53-20230912","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4269\/ajtmh.15-0087","article-title":"The post-2015 development agenda: keeping our focus on the worst off.","volume":"92","author":"Sharp","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"R54-20230912","doi-asserted-by":"crossref","first-page":"e112017","DOI":"10.1371\/journal.pone.0112017","article-title":"The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis.","volume":"9","author":"Odone","year":"2014","journal-title":"PLoS One"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201805000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:35:12Z","timestamp":1694558112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201805000-00017"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001784","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}